DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistanceNaoki Takegawa, Junji Tsurutani|International Journal of Cancer|2017Cited by 193
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Hidetoshi Hayashi et al.|Clinical Cancer Research|2018Cited by 169
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Kazuto Nishio, Takayuki Takahama et al.|The Oncologist|2020Cited by 95
[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplificationNaoki Takegawa, Kazuhiko Nakagawa|International Journal of Cancer|2019Cited by 90